Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 674 matching trials from the live ClinicalTrials.gov search.
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Ranibizumab, Peripheral Laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Diabetic Retinopathy, Diabetic Macular Edema, DME
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
MK-8748, Aflibercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
28
States / cities
Gilbert, Arizona • Glendale, California • Sacramento, California + 25 more
Conditions
Intracerebral Hemorrhage
Interventions
MW189, Saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 8 more
Conditions
Musculoskeletal Pain, Fractures, Closed, Distal Radius Fracture, Complex Regional Pain Syndromes
Interventions
Standard Care, Motor Representation Techniques
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
55 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Macular Edema, Epiretinal Membrane, Vitrectomy
Interventions
Dexamethasone
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diabetic Macular Edema
Interventions
K8
Drug
Lead sponsor
Michelle Abou-Jaoude
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Respiratory Failure
Interventions
Cuff Leak Test, Dexamethasone 4mg
Diagnostic Test · Drug
Lead sponsor
St. Joseph's Healthcare Hamilton
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Thyroid Eye Disease
Interventions
Veligrotug, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more
Conditions
Retinal Vein Occlusion
Interventions
Ranibizumab (Lucentis )
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Venous Leg Ulcer (VLU)
Interventions
Omeza OCM™ Wound Matrix, Routine Care
Device · Procedure
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lake Success, New York
Completed No phase listed Observational Accepts healthy volunteers

Inter-Device Reliability of the NPi-300 Pupillometer

NCT04993833
Conditions
Critical Illness, Neuropathy
Interventions
NPi-200 and NPi-300 pupillometers
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Macular Edema, Uveitis
Interventions
triamcinolone, ranibizumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Diabetic Macular Edema (DME)
Interventions
Remigromig, Ranibizumab
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
107
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more
Conditions
Acute Ischemic Stroke
Interventions
Endovascular Thrombectomy, Medical Management
Device · Other
Lead sponsor
Amrou Sarraj
Other
Eligibility
18 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Kansas City, Kansas • St Louis, Missouri + 3 more
Conditions
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
Genetic · Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
25 Years to 89 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, Imaging biomarker analysis, Photon Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, Faricimab, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
50
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 44 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Corticosteroid for Diabetic Macular Edema (DME) Study

NCT07843849
Conditions
Diabetic Macular Edema (DME), Diabetic Retinopathy
Interventions
Intravitreal dexamethasone implant
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Bone Marrow Edema
Interventions
Subchondroplasty
Procedure
Lead sponsor
Zimmer Biomet
Industry
Eligibility
40 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
6
States / cities
Encinitas, California • New Lenox, Illinois • New York, New York + 3 more
Conditions
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Retinal Vein Occlusion
Interventions
Dexamethasone intravitreal implant, Monthly Ranibizumab
Drug
Lead sponsor
Brian Burke, MPH
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Parkinson's Disease
Interventions
orally disintegrating selegiline (Zelapar)
Drug
Lead sponsor
Parkinson's Disease and Movement Disorder Center of Boca Raton
Other
Eligibility
30 Years to 90 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more